Literature DB >> 17893364

Crystal structure of activin receptor type IIB kinase domain from human at 2.0 Angstrom resolution.

Seungil Han1, Pat Loulakis, Matt Griffor, Zhi Xie.   

Abstract

Activin receptor type IIB (ActRIIB), a type II TGF-beta serine/threonine kinase receptor, is integral to the activin and myostatin signaling pathway. Ligands such as activin and myostatin bind to activin type II receptors (ActRIIA, ActRIIB), and the GS domains of type I receptors are phosphorylated by type II receptors. Myostatin, a negative regulator of skeletal muscle growth, is regarded as a potential therapeutic target and binds to ActRIIB effectively, and to a lesser extent, to ActRIIA. The high-resolution structure of human ActRIIB kinase domain in complex with adenine establishes the conserved bilobal architecture consistent with all other catalytic kinase domains. The crystal structure reveals that the adenine has a considerably different orientation from that of the adenine moiety of ATP observed in other kinase structures due to the lack of an interaction by ribose-phosphate moiety and the presence of tautomers with two different protonation states at the N9 nitrogen. Although the Lys217-Glu230 salt bridge is absent, the unphosphorylated activation loop of ActRIIB adopts a conformation similar to that of the fully active form. Unlike the type I TGF-beta receptor, where a partially conserved Ser280 is a gatekeeper residue, the AcRIIB structure possesses Thr265 with a back pocket supported by Phe247. Taken together, these structural features provide a molecular basis for understanding the coupled activity and recognition specificity for human ActRIIB kinase domain and for the rational design of selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893364      PMCID: PMC2204126          DOI: 10.1110/ps.073068407

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  27 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  Isolation and characterization of activin receptor from mouse embryonal carcinoma cells. Identification of its serine/threonine/tyrosine protein kinase activity.

Authors:  T Nakamura; K Sugino; N Kurosawa; M Sawai; K Takio; Y Eto; S Iwashita; M Muramatsu; K Titani; H Sugino
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

3.  Cloning and sequencing of a rat type II activin receptor.

Authors:  H Shinozaki; I Ito; Y Hasegawa; K Nakamura; S Igarashi; M Nakamura; K Miyamoto; Y Eto; Y Ibuki; T Minegishi
Journal:  FEBS Lett       Date:  1992-11-02       Impact factor: 4.124

Review 4.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

5.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

6.  Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.

Authors:  R Kambadur; M Sharma; T P Smith; J J Bass
Journal:  Genome Res       Date:  1997-09       Impact factor: 9.043

Review 7.  Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

Authors:  M E Noble; J A Endicott
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

Review 8.  Activin receptor-like kinases: structure, function and clinical implications.

Authors:  Heather Graham; Chun Peng
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2006-03       Impact factor: 2.895

Review 9.  Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders.

Authors:  Kunihiro Tsuchida
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2004-06

10.  Structural basis of inhibitor selectivity in MAP kinases.

Authors:  Z Wang; B J Canagarajah; J C Boehm; S Kassisà; M H Cobb; P R Young; S Abdel-Meguid; J L Adams; E J Goldsmith
Journal:  Structure       Date:  1998-09-15       Impact factor: 5.006

View more
  14 in total

1.  Peptide ligands that use a novel binding site to target both TGF-β receptors.

Authors:  Lingyin Li; Brendan P Orner; Tao Huang; Andrew P Hinck; Laura L Kiessling
Journal:  Mol Biosyst       Date:  2010-10-04

2.  Structural biology of the TGFβ family.

Authors:  Erich J Goebel; Kaitlin N Hart; Jason C McCoy; Thomas B Thompson
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

Review 3.  Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression.

Authors:  Richard L Cate
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

4.  Lysine conservation and context in TGFbeta and Wnt signaling suggest new targets and general themes for posttranslational modification.

Authors:  Charlotte E Konikoff; Robert G Wisotzkey; Stuart J Newfeld
Journal:  J Mol Evol       Date:  2008-09-17       Impact factor: 2.395

Review 5.  Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads.

Authors:  Apirat Chaikuad; Alex N Bullock
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-11-01       Impact factor: 10.005

Review 6.  Structural perspective of BMP ligands and signaling.

Authors:  Gregory R Gipson; Erich J Goebel; Kaitlin N Hart; Emily C Kappes; Chandramohan Kattamuri; Jason C McCoy; Thomas B Thompson
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

7.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

8.  Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation.

Authors:  Daniel Horbelt; Jan H Boergermann; Apirat Chaikuad; Ivan Alfano; Eleanor Williams; Ilya Lukonin; Tobias Timmel; Alex N Bullock; Petra Knaus
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

9.  Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing.

Authors:  Michael T Zimmermann; Raul Urrutia; Gavin R Oliver; Patrick R Blackburn; Margot A Cousin; Nicole J Bozeck; Eric W Klee
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

10.  Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-β signaling.

Authors:  Margot A Cousin; Michael T Zimmermann; Angela J Mathison; Patrick R Blackburn; Nicole J Boczek; Gavin R Oliver; Gwen A Lomberk; Raul A Urrutia; David R Deyle; Eric W Klee
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.